Our mission is to end breast cancer through the power of action and advocacy.
It is an honor to be part of this incredible coalition and to benefit firsthand from the resilience and dedication of our grassroots advocates, volunteer scientists, and committed donors. These stakeholders helped us make great progress in 2022 on our agenda to end breast cancer. And yet, at the same time, we lost thousands of women and men, including some of NBCC’s longtime leaders. Those losses are keenly felt and fuel our passion for our mission. We continue our work to protect future generations from breast cancer.

Our mission is, and always has been, to end breast cancer. That is the basis of the work we did in 2022 and will be our bedrock moving forward. We do not just say those words, we remain relentlessly committed to this work.

As you will see in this report, we continue to expand our education and training programs to reach advocates nationwide and globally. This year, our advocacy work was recognized by the American Association for Cancer Research, one of the largest science associations in the world. We continue to be a powerful voice for patients in the global science arena, especially through our clinical trials work. We again successfully secured an additional $150 million in research funding for the Department of Defense peer-reviewed Breast Cancer Research Program, and our trained advocates continued to influence how those research funds were allocated.

We expanded our Artemis Project to include new scientists and advocates, forming new research collaborations among participants that will save lives. As the Artemis preventive vaccine continued to move closer to a Phase 1 clinical trial, we began a strategic plan to institutionalize Artemis as a virtual collaboration entity, to preserve the long-term viability of this unprecedented science project.

As you may know, our work is complex, difficult, and very necessary. Your support of that work is vital to our success. I hope you find the summary of our work in 2022 compelling, and trust that your gifts are making a difference for hundreds of thousands of women and men today as well as for future generations.

Frances M. Visco
President, National Breast Cancer Coalition
MISSION

Our mission is to end breast cancer through the power of action and advocacy. NBCC has two arms: NBCCF, a 501 C(3) entity that educates and trains advocates to understand the language and concepts of science; collaborates with scientists and conducts research programs to advance an innovative agenda and influences the health care system to ensure access to quality care. Our 501 (c)(4) arm sets a public policy agenda and works to enact the necessary legislation, policy, and regulation to end breast cancer. This arm lobbies through its grassroots network for increased research funding, access to care, and expanded advocate involvement. Together, these two arms underpin our strategic approach to ending breast cancer.
RESEARCH

NBCC works to increase the effectiveness of breast cancer research in several ways.

Research Collaborations

NBCC leads collaborations that change the systems of research. Through our Artemis Project®, an innovative, mission-driven collaboration of advocates and scientists, we identify and answer the questions vital to ending breast cancer. Artemis focuses on Primary Prevention — how to stop women and men from getting breast cancer — and the Prevention of Metastasis — how to stop breast cancer from becoming lethal.

In March 2022, NBCC hosted its annual Artemis Project meeting, bringing together participants to develop plans of action to advance work on Artemis goals. The meeting on primary prevention culminated in research work plans related to localized therapies for risk reduction, strategies for improving risk prediction, and engineering an anti-breast cancer immune system. On preventing metastasis, the group catalyzed ideas about how to induce better immunity in primary tumors, how to potentially mobilize and destroy dormant disseminated tumor cells, and how to make disseminated tumor cells more immunogenic. Throughout the year, participants engaged in webinars and conference calls to refine plans, provide additional input, and evaluate possible new focus areas.

◆ Primary Prevention — The initial project undertaken by Artemis was to develop a safe and cost-effective vaccine targeting all three major subsets of breast cancer to reduce incidence and prevent death. NBCC continued to advance our preventive vaccine, which targets all major subsets of breast cancer, in partnership with the NCI Prevent program. (The NCI PREVENT Program supports, in their words, the best in cancer prevention that addresses unmet needs not adequately addressed by the private sector.) We now expect to launch a Phase 1 trial in 2023. NBCC filed for a provisional patent on the vaccine so that if it works, we can help ensure it is affordable and accessible globally.

◆ Prevention of Metastasis — Artemis participants initially focused on tumor dormancy and specifically whether the immune system interacts with dormant, disseminated tumor cells (DTCs) and how to intervene to stop them from becoming lethal. Independent of Artemis, several participants formed collaborations to advance ideas developed at Artemis, leveraging the project’s reach.

Clinical Trials

NBCC continued its collaboration with Translational Research in Oncology (TRIO) and Novartis on a clinical trial of CDK4/6 inhibitors in early high-risk HR+ breast cancer, the NATALEE trial. NBCC participates on the trial Steering Committee, the data safety monitoring board, and the translational research committee.

With these scientific-community collaborations, NBCC works to develop new research models, conduct research, design protocols, set research priorities and conduct research aimed at ending breast cancer.
OUTREACH

NBCC presented at or attended several national meetings on the issues of clinical trial research, patient advocate involvement in clinical trials, and research efforts. These included the ASCO Annual Meeting, the Cancer Research UK Grand Challenge Summit, the Integration Panel of the Department of Defense Breast Cancer Research Program, the National Cancer Reporting Fellowship training hosted by the Association of Healthcare Journalism, the NCI Council for Research Advocates meeting, and the San Antonio Breast Cancer Symposium.

As a grassroots organization, NBCC recognizes the importance of an empowered public and provides the public with evidence-based and patient-centered information on important breast cancer issues and research.

As part of that work, we publish Science Spotlights which provide in-depth analyses of recently published breast cancer research, the results of pivotal breast cancer clinical trials, and other newsworthy breast cancer information. In 2022, NBCC published seven articles discussing key research presented at major conferences, as well as features on new drug approvals in breast cancer.
EDUCATION AND TRAINING

NBCC’s organizational mandate is to train and develop a strong, knowledgeable nationwide network of breast cancer advocates.

NBCC knows that we will only end breast cancer if trained, educated advocates play a leadership role in getting there. Our education and training programs are designed to empower advocates by teaching them the complexities of breast cancer science, research, and the public policy process to ensure their voice is not only heard but provokes system change.

Project LEAD® Institute — NBCC hosted two, in-person sessions of the Project LEAD Institute where we educated more than 60 advocates from across the country, and around the globe, in breast cancer biology and genetics, epidemiology, immunology, and clinical trial design.

Advanced Project LEAD — Advanced Project LEAD advocates participated in an exclusive webinar with Dr. Steven Vogl on the current state of cancer research and medical care in the United States and across the globe. Additionally, a Breast Cancer Models project, driven by a group of Advanced LEAD advocates, continues to make progress. To aid advocates in understanding what models are used in cancer research and why, this project is developing a hierarchy of models, a glossary of terms, and a comprehensive white paper based on literature reviews and interviews with breast cancer researchers.

Continuing Education — NBCC conducted numerous webinars on various topics, including two multi-part series on critical appraisal and the demystification of IRBs, among others. NBCC also hosted two in-person Advanced Topic Sessions for Project LEAD graduates: “Application of Advanced Technologies Like CRISPR in Breast Cancer Research” and “The Future of HER2 Low Breast Cancer.”

Learning Management System (LMS) — NBCC’s online education portal completed pilot testing and will roll out to a broader advocate user base in 2023. Current programming consists of seven education modules, including clinical trial methodology, patient-reported outcomes and measurements, ethical issues in clinical trial conduct, and the use of models in breast cancer research. The creation of new learning modules is ongoing.

Advocate Leadership Summit — More than 120 dedicated NBCC advocates attended NBCC’s Advocate Leadership Summit in Washington, D.C., the first to be held in person since 2019. Session topics included “Getting to Value-Based Cancer Care,” “Breast Cancer Disparities: Advancing Health Equity in Cancer Care,” “New Horizons in Cancer Metastasis Research,” “Congress 101: Navigating Capitol Hill for Advocates,” “Advocacy When the House is On Fire: How Grassroots Organizations can Save Democracy and Still Accomplish their Goals,” and an update on the work of NBCC’s Artemis Project. The program also included remarks from U.S. Representative Jamie Raskin and a Q&A session with NBCC President Fran Visco.
PUBLIC POLICY

The NBCC Board of Directors establishes NBCC’s legislative and public policy priorities each year. In 2022, NBCC made significant progress on its priorities.

◆ **Annual Membership Lobby Day** — Advocates held more than 200 meetings with their members of Congress to push for the adoption of NBCC legislative priorities. In home districts, advocates attended virtual town halls and published letters to the editor in local papers to advocate for NBCC priorities.

◆ **Team Leader Training** — NBCC maintains a network of Team Leaders who are trained to lead advocates throughout the year in advancing our Policy agenda. During the virtual 2022 Team Leader Training, NBCC educated Team Leaders on how Congress works, committee structure and process, regulatory process, strategic approaches to developing a policy agenda, communicating effectively with policymakers, how to grow an advocacy network, and other relevant topics. NBCC Team Leaders participated in monthly Zoom meetings to stay updated on legislative and public policy priorities.

◆ **Breast Cancer Caucus** — NBCC’s Breast Cancer Caucus educates voters and candidates that breast cancer is a political issue. The Breast Cancer Caucus raises awareness and support for NBCC’s public policy priorities through voter and candidate education and get-out-the-vote activities. In 2022 the Breast Cancer Caucus engaged mid-term voters via a campaign where NBCC advocates sent Caucus branded GOTV postcards to their networks of family and friends, positioning breast cancer as an issue influencing voters in the mid-term elections.

Legislative Priorities:

◆ **DOD Breast Cancer Research Program** — In 1992, the Department of Defense Breast Cancer Research Program (DOD BCRP) started because of NBCC’s campaign to increase federal appropriations for breast cancer research. Through NBCC’s advocacy work, Congress approved $150 million in FY23.

◆ **Metastatic Breast Cancer Access to Care Act**— NBCC’s advocates were responsible for obtaining strong bipartisan support for our priority legislation, S. 1312/H. R. 3183, the Metastatic Breast Cancer Access to Care Act, which NBCC initiated. This bill waives Social Security and Medicare waiting periods for people living with metastatic breast cancer.

◆ **Preservation of the Medicaid Breast and Cervical Cancer Treatment Program** — Congress enacted the Breast and Cervical Cancer Treatment Act in 2000 after years of NBCC grassroots lobbying and influence. NBCC remains committed to ensuring all women and men screened and diagnosed with breast cancer have access to the treatment they need.
At the end of the 117th Congress in 2022, NBCC advocacy resulted in 240 bipartisan cosponsors in the House and 29 in the Senate. NBCC advocates engaged in intense end-of-year advocacy aimed at having this legislation attached to the omnibus spending package.

While that effort was unsuccessful, NBCC raised awareness and created strong momentum for enactment in the 118th Congress in 2023.

Public Policy Priorities:
NBCC develops public policy priorities to advance non-legislative issues that are important to ending breast cancer. NBCC evaluates laws and regulations against these policies, and takes appropriate action when needed.

◆ Guaranteed Access to Quality Care for All — NBCC supports health care access initiatives that expand access to Medicare while also offering a private insurance option, automatically enrolling individuals who do not have access to other coverage, and providing guaranteed benefits including primary and preventative care, hospital services, and prescription drug coverage.

◆ Access to Affordable & Effective Therapies — NBCC supports policies that address systemic deficiencies in the law, regulation, and science policy resulting in drug approvals that do not significantly extend or save lives and whose prices are not based on value or effectiveness based on Board adopted principles.

◆ Educated Patient Advocate Participation — NBCC continues to work to ensure that educated patient advocates who represent a constituency have a meaningful seat at the table in all levels of health care and breast
SPECIAL EVENTS

Les Girls
NBCC’s signature fundraising event, Les Girls Cabaret, was held at Paramount Studios on October 23rd 2022. The event included celebrity appearances from Jennifer Coolidge and performances from Merle Dandridge, Chris Gorham, and Marilu Henner. The 2022 event raised a record breaking amount and was full of fun, song and celebration.

NYC Women With Balls®
The New York Women With Balls bowling event was held in person on 10/17 at Frames NYC. NBCCF Board member Liane Martins Lindner continued to serve as our Event Chair. This unique event offers a fun opportunity for people to raise funds to support NBCC. It continues to grow in popularity and raised the most in its 5-year history in 2022.
YOUR DOLLARS AT WORK

2022 Expenses $3,665,990*

<table>
<thead>
<tr>
<th>Category</th>
<th>Expense</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management &amp; General</td>
<td>21%</td>
</tr>
<tr>
<td>Catalytic Research</td>
<td>21%</td>
</tr>
<tr>
<td>Public Policy</td>
<td>13%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>7%</td>
</tr>
<tr>
<td>Public Information</td>
<td>7.5%</td>
</tr>
<tr>
<td>Education &amp; Training</td>
<td>37.5%</td>
</tr>
<tr>
<td>Grassroots, etc.</td>
<td>7%</td>
</tr>
<tr>
<td>Other Programs</td>
<td>1%</td>
</tr>
</tbody>
</table>

*Pie-chart reflects expenses of $3,489,180
   It does not include event related direct benefits to donors of $176,810

Assets 2022

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$4,477,387</td>
</tr>
<tr>
<td>Accounts Receivables</td>
<td>$1,288,287</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$178,046</td>
</tr>
<tr>
<td>Net Property &amp; Equipment</td>
<td>$21,652</td>
</tr>
<tr>
<td>Deposits</td>
<td>—</td>
</tr>
</tbody>
</table>

TOTAL ASSETS $5,965,372

LIABILITIES $177,782

TOTAL NET ASSETS $5,787,590

TOTAL LIABILITIES & ASSETS $5,965,372

2022 Public Support & Other Revenue $4,741,148*

<table>
<thead>
<tr>
<th>Category</th>
<th>Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Revenue</td>
<td>2% $96,319</td>
</tr>
<tr>
<td>Corporation &amp; Foundations</td>
<td>10.3% $488,094</td>
</tr>
<tr>
<td>Restricted Grants</td>
<td>51.8% $2,456,112</td>
</tr>
<tr>
<td>Special Events</td>
<td>14.5% $688,572</td>
</tr>
<tr>
<td>Individuals</td>
<td>21.4% $1,012,050</td>
</tr>
</tbody>
</table>

*Total Expense and Total Revenue include event costs that are direct benefits to donors, $176,810.
2022 BOARD OF DIRECTORS

ABCD: After Breast Cancer Diagnosis
Bonnie Anderson (D)
Linda Hansen (A)

Alamo Breast Cancer Foundation
Jerry Worden (D)
Beth Emery (A)

American Association of Breast Care Professionals
Rhonda Turner (D)
Gretchen Walton (A)

Annie Appleseed Project
Ann Fonfa (D)
Rasheedah Ahmad (A)

Breast Cancer Care and Research Fund
Michele Rakoff (D)
Michele Atlan (A)

CARE Advocates Network
Carol Matyka (D)
Karen Poliseno (A)

Cedar Valley Cancer Committee: Beyond Pink TEAM
Christine Carpenter (D)
Lori Seawel (A)

Cedars Sinai Breast Center
Sherry Goldman (D)
Sylvia Estradal (A)

Delaware Breast Cancer Coalition, Inc.
Francesca Vogel(D)
Susan Murray (A)

Dr. Susan Love Research Foundation
Judi Hirshfield-Bartek (D)
Christopher Clinton Conway (A)

Florida Breast Cancer Foundation
Valencia Robinson (D)
Judy Perkins (A)

Lobular Breast Cancer Alliance
Laurie Hucheson (D)
Mason Mitchell-Daniels (A)

Metropolitan Washington, DC Chapter of NBCC
Tania Chomiak-Salvi (D)
Wanda Lucas (A)

Michigan Breast Cancer Coalition
Rose Marie Sitko (D)
Jeanne Deneweth (A)

Minnesota Breast Cancer Coalition
Christine Norton (D)
Pat Haugen (A)

National Breast Cancer Coalition
Frances M. Visco (D)

Nueva Vida
Astrid Jiménez, Esq. (D)
Gloria Elliott (A)

SHARE
Jennie Santiago (D)
Stephanie Poland (A)

Virginia Breast Cancer Foundation
Marylinn Minor (D)
Katy Sawyer (A)

Young Survival Coalition
Joy Simha (D)

A = Alternate

In Memoriam: Carol Vance Wall

2022 BOARD OF TRUSTEES

Alec R. Call
Beth Emery, JD
Sherry Goldman RN, NP, MSN
Ira Hillman, Treasurer
Judi Hirshfield-Bartek, RN, MS, OCN
Bryan Johns
Liane Martins Lindner, Chair

Christine Norton, MA, Secretary
Michele Rakoff
Linda Rothweiler, DMD, Vice Chair
Dennis Slamon, MD, PhD
Frances M. Visco, JD
Douglas Wall, MBA
Ann C. Yahner, JD

In Memoriam: Carol Vance Wall
2022 DONORS

Corporations, Foundations and Donor Advised Funds

Amazon Smile Foundation
Alan Sieroty Charitable Fund
Angelo Family Charitable Fund
Arizona Gatorade Boys Cross Country
Barbara Silver Levin Foundation
Bessemer Trust
Beth Sieroty Meltzer Fund
Bisceglio Fernandez Fund
Boston Foundation
Broad Survivors Trust
Brown Rudnick
Cardoso Family Foundation
Cedar Valley Cancer Committee: Beyond Pink TEAM
Cedars Sinai Breast Center
Costigan Family Gift Fund
Dermod and Christine Norton Family Charitable Fund
Edward Jones Charitable Gift Fund
Eisenberg, Rothweiler, Winkler, Eisenberg & Jeck, P.C.
Elm Street Foundation
Exact Sciences
Fitzgerald Giving Fund
Forbes Family Charitable Account
Gantswig-Welinsky Fund
George and Amy Klette Newman Foundation
Ira Hillman & Jeremy Barber Family Fund
iS CLINICAL by INNOVATIVE SKINCARE
James and Deborah Burrows Foundation
Jewish Federation of St. Louis
Jill Grey Family Charitable Foundation
Joyce and Irving Goldman Family Foundation
JT Charitable Fund
Judges & Lawyers Breast Cancer Alert
Judy and Peter Blum Kovler Foundation
Kretzman Family Charitable Fund
Linda Creed Breast Cancer Organization
Lloyd-Sorkin Charitable Trust
Luis & Lee Lainer Fund
Luling High School — Student Activity Fund
Martin Gruber Fund
Match Sanderson Foundation
Maurice and Lena Russo Family Foundation
May and Walt Family Charitable Fund
Mellam Family Foundation
Merck & Co., Inc.
Michael Dunitz Crisis Foundation, Inc.
Michele Asselin and J. Meltzer Fund
Minnesota Breast Cancer Coalition
Mueller Family Foundation
Musa and Tom Mayer Charitable Fund
National Philanthropic Trust
National Sportsmanship Foundation Inc.
Novartis Oncology
Pfizer, Inc.
Progressive Jewish Fund
Purcell Fund
Quantbot Technologies, LP
R & L Donner Trust
Richard and Hinda Rosenthal Foundation
Richard and Suzanne Kayne Charitable Fund
Riskified
Rita J. & Stanley H. Kaplan Family Foundation, Inc.
RMF Foundation
Robert S. Fleischer and Susan L. Raanan Charitable Fund
Roskam Family Giving Fund
Safra National Bank
Sandra Shorenstein & Gregory Kuhn Fund
Schnader Harrison Segal & Lewis LLP
Sevenwinds Casino, Lodge & Conference Center
Stephen Moeller and Vivian Arias Charitable Fund
Steve Tisch Family Foundation
Suzanne H. Kaye Advocacy Fund
Sylvan C. Coleman Trust
The Alfred and Rosemary Iversen Family Foundation
The Biondi Family Fund
The David and Nancy Poorvu Charitable Trust
The David Geffen Foundation
The Foundation for Delaware County
The Herbert McLaughlin Children’s Trust
The Horn Foundation
The Jordan-Evans Family Foundation
The Robert and Shirley Harris Family Foundation
The Wonderful Company Foundation
Translational Research in Oncology-US, Inc. (TRIO-US)
TRIO
Vance Wall Foundation
VerSteeg & Pierson Giving Fund
Williams Giving Fund
Young Conaway Stargatt & Taylor, LLP
## 2022 DONORS

### Individuals

<table>
<thead>
<tr>
<th>Greater than $1M</th>
<th>Gifts from $500,000 to $999,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carol* and Terry Wall</td>
<td>Dorian S. Goldman and Marvin Israelow</td>
</tr>
<tr>
<td></td>
<td>Katja Goldman and Michael Sonnenfeldt</td>
</tr>
<tr>
<td></td>
<td>Lloyd and Victoria Goldman</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gifts from $250,000 to $499,999</th>
<th>Gifts from $100,000 to $249,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alec Call and Bryan Johns</td>
<td>Musa and Tom Mayer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gifts from $25,000 to $49,999</th>
<th>Gifts from $5,000 to $9,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Coolidge</td>
<td>Judy and Peter Kovler</td>
</tr>
<tr>
<td>Cindy and Alan Horn</td>
<td>Peter Morton</td>
</tr>
<tr>
<td>Linda Essakow and Stephen Gunther</td>
<td>Melinda Nordeng</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gifts from $1,000 to $4,999</th>
<th>Gifts from $100,000 to $249,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramesh and Sina Akhtarzad</td>
<td>Madeline and Stephen Anbinder</td>
</tr>
<tr>
<td>Michael and Carla Angelo</td>
<td>Alan Appelbaum</td>
</tr>
<tr>
<td>Susan and Robert Appleton</td>
<td>Michele Asselin and Joseph Meltzer</td>
</tr>
<tr>
<td>Beau and Laura Avril</td>
<td>Annette Bar-Cohen</td>
</tr>
<tr>
<td>Andrea Baum</td>
<td>Allen Baum</td>
</tr>
<tr>
<td>Susan Bay-Nimoy</td>
<td>Joshua Beal</td>
</tr>
<tr>
<td>Jennifer and Matthew Berzok</td>
<td>Carol Biondi</td>
</tr>
<tr>
<td>Carole Bischeglio, PhD</td>
<td>Isabelle T. Bisceglio, PhD</td>
</tr>
<tr>
<td>Phillip and Nina Blumenfeld</td>
<td>Carmella Bocchino</td>
</tr>
<tr>
<td>Corlis Boggs</td>
<td>Byron Capps</td>
</tr>
<tr>
<td>Ruth and Peter Brooke</td>
<td>Christine B. and Delburn Carpenter</td>
</tr>
<tr>
<td>Shirley H. Brown</td>
<td>Richard Cassese</td>
</tr>
<tr>
<td>Joe Camardo, MD</td>
<td>Roger Spottswoode</td>
</tr>
<tr>
<td>Stan and Mary Friedman</td>
<td>Henry and Arline Gluck</td>
</tr>
<tr>
<td>Suzanne and Ric Kayne</td>
<td>Diana Wendy and Hugh Kendrick</td>
</tr>
<tr>
<td>Michele May and David R. Walt, PhD</td>
<td>Arik Preis</td>
</tr>
<tr>
<td>Abbie Lee and William G. Warden IV</td>
<td>Martha Williams</td>
</tr>
<tr>
<td>Kathy M. Ball</td>
<td></td>
</tr>
</tbody>
</table>
Margaret Clarke
Elaine M. Coughlin
Jayanta Debnath, MD
Maria Driscoll
Donna M. Duncan
Dale and Harry Eastman
Paul Emery
Carol Evans
Ileana and Irvin Fagin
Kathleen Fernan
Kathleen Fitzgerald
Judy and Tom Flesh
Sean Francis
Elizabeth and Richard Frank
Paula Freiburger
Muriel L. Frischer, PhD
Henry Furst
Karren Ganstwig and Howard Welinsky
Monah and Alan Gettner
Caitlin and Cyrus Ghajar
Patricia L. Glaser
Jeri and David Glaser
Carole Goldberg
Jeffrey C. Golden
Sherry and Barry Goldman
George T. Grant
Adam Greene
Lisa & Joshua Greer
Janet and Wayne Gretzky
Jill Grey
Lauren Gross
Donald Grosset
Martin Gruber
Susan R. Hester
Michele Hille
Judi J. Hirshfield-Bartek and Elmer Bartek
Roberta Holstein
Keith Hurvitz, MD and Sara Hurvitz, MD
Laurie Hutcheson
Lonnie L. Israel
Gail Israel
Rosemary and Alfred W. Iversen
Harris S. Jaffe
Caroline Jett-Sun
Jeffrey Johns
Gail Kamer Lieberfarb
Dennis and Julie Kiraly
Ethel Klein
Caron Klein
Scott and Melissa Klein
Keith and Nancy Krakaur
Robert K. Kretzman
Gregory Kuhn
Luis and Lee Lainer
Meghan Landymore
Deborah Laub
Barbara E. Lazaroff
Marva Lewis McKnight
Karen and Franklin Lewkowitz
Liane Martins
Susan F. and James E. Lindsay
Marie Lippman
Nancy Lisagor, PhD
Lawrence B. Ludwig
H. Kim Lyerly, MD
Ngina Lythcott, PhD and Byllye Avery
Dennis Magr dhcpian
Christopher Marin
Joanne Marquardt
Carol Matyka
Mary Matyka
Jacqueline McMullen
Molly Mead
Catherine M. Meek and Al Earle
Beth Sieroty Meltzer
Nikki and Joel Miliband
Laura A. Miller
Stephen Moeller and Vivian Arias
Martha Moroney
Pamela Morton
Todd Nickey and Greg Holcomb
Bill Nye
Joshua and Laurie Olshansky
Robin Ozerkis
Lydia B. Parnes
James D. Parriott and Diane Cary
Lori Petitti
Karen Polisen0
Nancy Poorvu
Richard and Debbie Powell
Christopher Prendergast
Nancy and Coy Purcell
Robert Fleischer and Susan Raanan
Jay Race
Jane Rascoff
Pamela Romanow
Janice Rosenhaus
Skip and Marilyn Rosskam
Rosemary Rosso
Beth Rothschild
Bernice Rudolph
Rosemary Ruggiero
Phoebe Scherer
Helen Schiff and Richard Congress
Helena Schwartz
Gail and Steven Shak
Sandra Shorenstein
Lauren Shuler Donner
Robert Simmons
Dennis Slamon, MD and Obie Slamon
Sherri Stahl
Lisabeth Tarlow
Gomer Thomas
Katherine Tobin
Michelle and Stephen Tregear
Amedeo Ursini
John VerSteeg and Jane Pierson
Gary and Elizabeth Wohl
Melanie Wyne
Carol Zipkin Earle

Bequests
Beatrice Lemlein*
Gary Ponali*
Elaine Soter*

*deceased
The National Breast Cancer Coalition Fund is the 501 (c)(3) arm of NBCC, that designs and runs programs to educate, train, and inform advocates, policymakers, scientists, providers, and the public about breast cancer science, health care and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all, and gives a powerful, effective voice to breast cancer advocates everywhere.

The National Breast Cancer Coalition, NBCC’s 501 (c)(4) arm, sets a public policy agenda and then works to enact the necessary legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.